In a recent meeting with some investigators, we discussed the protocol for a phase II clinical trial. When I ask whether or not if we need to consider the interim analysis, several investigators immediately oppose it citing that it will cost us the p-values. It seems that the investigators have been well informed the multiplicity and alpha-spending issue for the interim analysis or multiple look at the data.
I have a feeling that investigators seems to be afraid of the interim analysese because it may cost the power for the final analysis.
Yes, Its true
ReplyDelete